Primary regulatory
Rapamune (sirolimus) Label Information
FDA-approved prescribing label for Rapamune (sirolimus), indicated for prophylaxis of organ rejection in kidney transplant patients and for the treatment of lymphangioleiomyomatosis (LAM).
U.S. Food and Drug AdministrationPublished Sep 1, 2023Accessed Jul 1, 2026
Registry record
Source metadata
- Publisher
- U.S. Food and Drug Administration
- Source type
- Primary regulatory
- Registry ID
fda-rapamune-label
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.